Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|10|6|519-529

ISSN： 1389-4501

Source： Current Drug Targets, Vol.10, Iss.6, 2009-06, pp. : 519-529

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents

By Zimarino Marco   Renda Giulia   Raffaele De Caterina  

Drugs, Vol. 65, Iss. 6, 2005-01 ,pp. : 725-732

Adis International

Access to resources Recommend Favorite

Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents

By  

Current Clinical Pharmacology, Vol. 8, Iss. 1, 2013-02 ,pp. : 59-66

Bentham Science Publishers

Access to resources Recommend Favorite

Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.

By  

Current Clinical Pharmacology, Vol. 8, Iss. 4, 2013-11 ,pp. : 340-349

Bentham Science Publishers

Access to resources Recommend Favorite

Dual antiplatelet therapy (DAT) was associated with an increased haemorrhage risk after drug-eluting stent (DES) placement

By  

Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. : 25-25

Adis International

Access to resources Recommend Favorite

Drug-Eluting Stents

By  

Heart Drug, Vol. 3, Iss. 4, 2004-02 ,pp. : 203-213

Karger

Access to resources Recommend Favorite